Target Name: SLC6A8
NCBI ID: G6535
Other Name(s): solute carrier family 6 (neurotransmitter transporter), member 8 | CRT1 | CT1 | Solute carrier family 6 (neurotransmitter transporter, creatine) member 8 | SLC6A8 variant 3 | CRTR | solute carrier family 6 member 8 | Solute carrier family 6 member 8 | Sodium- and chloride-dependent creatine transporter 1 (isoform 1) | Solute carrier family 6 (neurotransmitter transporter, creatine), member 8 | Sodium- and chloride-dependent creatine transporter 1 (isoform 3) | SC6A8_HUMAN | Solute carrier family 6 (neurotransmitter transporter, creatine) member 8 (SLC6A8) | solute carrier family 6 (neurotransmitter transporter, creatine), member 8 | Sodium- and chloride-dependent creatine transporter 1 | CTR5 | CCDS1 | CRT-1 | Solute carrier family 6 member 8, transcript variant 3 | CRT | Creatine transporter SLC6A8 variant D | Creatine transporter 1 | creatine transporter 1 | creatine transporter SLC6A8 variant D | Solute carrier family 6 member 8, transcript variant 1 | SLC6A8 variant 1 | Solute carrier family 6 (neurotransmitter transporter), member 8

SLC6A8: A Potential Drug Target and Biomarker for Neurotransmitter Transporter

SLC6A8, a member of the SLC6A family, is a protein that is expressed in various tissues of the brain and plays a critical role in neurotransmitter transporter. It is a transmembrane protein that is composed of an intracellular N-terminus, a catalytic C-terminus, and an extracellular C-terminus. SLC6A8 is involved in the transport of various neurotransmitters, including dopamine, serotonin, and endocannabinoids.

SLC6A8 is a well-established gene that has been studied extensively in the context of neurotransmitter transport. It is highly expressed in the brain and is mainly expressed in the prefrontal cortical regions of the brain. SLC6A8 is also expressed in other tissues, including the liver, heart, and kidney.

SLC6A8 has been identified as a potential drug target due to its involvement in neurotransmitter transport. The neurotransmitters that are transported by SLC6A8 can play a crucial role in the function of the brain and are involved in various neurological disorders, including depression, anxiety, and neurodegenerative diseases.

SLC6A8 has also been identified as a potential biomarker for neurodegenerative diseases. The loss of SLC6A8 has been observed in various neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease. The decreased expression of SLC6A8 has been observed in the brains of individuals with these disorders, which suggests that it may be a useful biomarker for the diagnosis and progression of these diseases.

In addition to its potential drug and biomarker applications, SLC6A8 is also involved in the regulation of neurotransmitter transport. SLC6A8 is a member of the T-type Ca2+-ATPase (Ca2+-ATPase) family, which is involved in the regulation of intracellular Ca2+ levels. The Ca2+-ATPase is a critical enzyme that is involved in various physiological processes, including neurotransmitter transport.

SLC6A8 is also involved in the regulation of neurotransmitter transport in the nervous system. SLC6A8 is a component of the neurotransmitter transporter complex, which is responsible for the transport of neurotransmitters across the blood-brain barrier. The neurotransmitter transporter complex is a critical pathway for the delivery of neurotransmitters to the brain and is involved in the regulation of various neurological disorders, including depression and anxiety.

In conclusion, SLC6A8 is a well-established protein that is involved in the transport of neurotransmitters across the blood-brain barrier. Its involvement in neurotransmitter transport and regulation makes it a potential drug target and biomarker for various neurological disorders. Further research is needed to fully understand the role of SLC6A8 in neurotransmission and to develop effective treatments for neurodegenerative diseases.

Protein Name: Solute Carrier Family 6 Member 8

Functions: Creatine:sodium symporter which mediates the uptake of creatine (PubMed:7953292, PubMed:7945388, PubMed:9882430, PubMed:17465020, PubMed:22644605, PubMed:25861866). Plays an important role in supplying creatine to the brain via the blood-brain barrier (By similarity)

More Common Targets

SLC6A9 | SLC7A1 | SLC7A10 | SLC7A11 | SLC7A11-AS1 | SLC7A13 | SLC7A14 | SLC7A2 | SLC7A3 | SLC7A4 | SLC7A5 | SLC7A5P1 | SLC7A5P2 | SLC7A6 | SLC7A6OS | SLC7A7 | SLC7A8 | SLC7A9 | SLC8A1 | SLC8A1-AS1 | SLC8A2 | SLC8A3 | SLC8B1 | SLC9A1 | SLC9A2 | SLC9A3 | SLC9A3-AS1 | SLC9A4 | SLC9A5 | SLC9A6 | SLC9A7 | SLC9A7P1 | SLC9A8 | SLC9A9 | SLC9A9-AS1 | SLC9B1 | SLC9B1P2 | SLC9B2 | SLC9C1 | SLC9C2 | SLCO1A2 | SLCO1B1 | SLCO1B3 | SLCO1B7 | SLCO1C1 | SLCO2A1 | SLCO2B1 | SLCO3A1 | SLCO4A1 | SLCO4A1-AS1 | SLCO4C1 | SLCO5A1 | SLCO6A1 | SLED1 | SLF1 | SLF2 | SLFN11 | SLFN12 | SLFN12L | SLFN13 | SLFN14 | SLFN5 | SLFNL1 | SLFNL1-AS1 | SLIRP | Slit | SLIT1 | SLIT2 | SLIT2-IT1 | SLIT3 | SLIT3-AS2 | SLITRK1 | SLITRK2 | SLITRK3 | SLITRK4 | SLITRK5 | SLITRK6 | SLK | SLMAP | SLMO2-ATP5E | SLN | SLPI | SLTM | SLU7 | SLURP1 | SLURP2 | SLX1A | SLX1A-SULT1A3 | SLX1B | SLX1B-SULT1A4 | SLX4 | SLX4IP | SLX9 | SMAD | SMAD1 | SMAD1-AS1 | SMAD1-AS2 | SMAD2 | SMAD3 | SMAD4